Pharmacology  ·  Antibacterial Agents

Cephalosporins & Beta-Lactamase Inhibitor Combinations

Generation spectrum, inhibitor classes, cross-reactivity, and clinical selection

Abbreviations: PBP = penicillin-binding protein  ·  MSSA = methicillin-susceptible Staphylococcus aureus  ·  MRSA = methicillin-resistant Staphylococcus aureus  ·  ESBL = extended-spectrum beta-lactamase  ·  KPC = Klebsiella pneumoniae carbapenemase  ·  NDM = New Delhi metallo-beta-lactamase  ·  VIM = Verona integron-encoded metallo-beta-lactamase  ·  AmpC = AmpC beta-lactamase  ·  CAP = community-acquired pneumonia  ·  CSF = cerebrospinal fluid  ·  fT>MIC = free drug time above minimum inhibitory concentration

Cephalosporin Generations — Spectrum and Clinical Use
Generation Key Agents Gram-Positive Gram-Negative Primary Clinical Use
1st Cefazolin (IV), Cephalexin (oral) Excellent — MSSA, streptococci E. coli, Proteus mirabilis, Klebsiella (non-ESBL) Surgical prophylaxis; MSSA skin, soft tissue, and bone infections
2nd Cefuroxime; Cefoxitin / Cefotetan (cephamycins) Good + H. influenzae, M. catarrhalis; cephamycins add Bacteroides fragilis Respiratory infections (cefuroxime); intra-abdominal / gynecologic (cephamycins)
3rd Ceftriaxone, Cefotaxime, Ceftazidime Moderate (reduced vs. 1st gen) Broad Enterobacteriaceae; N. gonorrhoeae; ceftazidime adds Pseudomonas Bacterial meningitis; CAP; gram-negative bacteremia; gonorrhea
4th Cefepime Good — comparable to 1st gen Pseudomonas; AmpC-stable; ESBL-susceptible Febrile neutropenia; nosocomial infections; Pseudomonas coverage needed
5th Ceftaroline; Ceftolozane-tazobactam MRSA + MSSA + streptococci (ceftaroline) Enterobacteriaceae (ceftaroline); enhanced Pseudomonas, AmpC (ceftolozane-tazo) Skin and soft tissue (MRSA); CAP; MDR Pseudomonas (ceftolozane-tazo)
Beta-Lactamase Inhibitor Combinations
Classical Inhibitors
Clavulanate / Sulbactam / Tazobactam
  • Irreversible (suicide) inhibitors of Class A serine beta-lactamases
  • No activity vs. Class B metallo-beta-lactamases (NDM, VIM) or Class C AmpC
  • Amoxicillin-clavulanate: oral; H. influenzae, Moraxella, community E. coli
  • Piperacillin-tazobactam: broad IV coverage including Pseudomonas
  • Sulbactam: intrinsic activity vs. Acinetobacter baumannii
  • Inoculum effect: unreliable for ESBL bacteremia despite in vitro susceptibility
Novel Inhibitors (Diazabicyclooctane / Boronate)
Avibactam / Relebactam / Vaborbactam
  • Reversible inhibitors — regenerated after enzyme inactivation
  • Cover Class A (ESBL, KPC), Class C (AmpC), some Class D — not Class B
  • No activity vs. metallo-beta-lactamases (NDM, VIM, IMP)
  • Ceftazidime-avibactam: KPC-producing carbapenem-resistant organisms
  • Imipenem-relebactam, meropenem-vaborbactam: similar KPC coverage
  • Genotypic testing essential — KPC vs. NDM determines which agent works
Pharmacokinetics and Cross-Reactivity
Agent Elimination Renal Adjustment CSF Penetration Key Notes
Cefazolin Renal Yes Poor (meningitis not an indication) Lowest penicillin cross-reactivity risk — safe in most penicillin allergy for surgical prophylaxis
Ceftriaxone Biliary 40% + renal 60% No Good (inflamed meninges) Preferred for bacteremia in renal failure; avoid in neonates; no co-administration with IV calcium
Ceftazidime Renal Yes Adequate Only 3rd-gen agent with Pseudomonas coverage; gram-negative meningitis including Pseudomonas
Cefepime Renal Yes — essential Good (inflamed meninges) Accumulation causes neurotoxicity — non-convulsive status epilepticus, myoclonus; review dose in renal impairment
Ceftaroline Renal Yes Limited Only beta-lactam active against MRSA via PBP2a binding; no Pseudomonas or anaerobe coverage
Penicillin Cross-Reactivity — The Side-Chain Rule
The Rule
Side Chain Drives Risk, Not the Ring
  • True cross-reactivity ~1–2% — the 10% figure is not supported by current evidence
  • Immunologic risk is mediated by shared 7-position R1 side chains, not the shared beta-lactam ring
  • Structurally dissimilar penicillin and cephalosporin = minimal shared risk
Low Risk
Cefazolin
  • Side chain structurally unrelated to any penicillin
  • Lowest cross-reactivity risk of any cephalosporin
  • Safe for surgical prophylaxis in most penicillin-allergic patients after allergy risk stratification
Higher Risk
Cefadroxil / Cefprozil
  • Share 7-position side chain with amoxicillin
  • Meaningfully higher cross-reactivity in documented amoxicillin allergy
  • Avoid or use with caution in confirmed amoxicillin-allergic patients

Clinical Rules: Generation Selection, Ceftriaxone, and Cefepime Neurotoxicity

Use first-generation cefazolin for surgical prophylaxis and MSSA infections — it is the preferred penicillinase-stable agent when IV access is required and MRSA is not a concern. Use third-generation ceftriaxone for gram-negative bacteremia, CAP, and meningitis caused by susceptible organisms; its biliary elimination spares dose adjustment in renal failure.

Cefepime neurotoxicity is underrecognized: any unexplained encephalopathy, myoclonus, or altered consciousness in a patient receiving cefepime should prompt immediate dose review (adjust for current renal function), electroencephalogram evaluation for non-convulsive status epilepticus, and consideration of switching to an alternative agent.

Novel inhibitor combinations (ceftazidime-avibactam, meropenem-vaborbactam) cover KPC but not NDM. Confirm resistance genotype before selecting therapy for carbapenem-resistant organisms — treating NDM with ceftazidime-avibactam alone is ineffective.

Suggested References

Author / Source Title Publication
Katzung BG, ed. Basic and Clinical Pharmacology, 15th ed. — Chapter 43: Beta-Lactam Antibiotics McGraw-Hill, 2021
Brunton LL, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. — Chapter 50: Penicillins, Cephalosporins, and Other Beta-Lactam Antibiotics McGraw-Hill, 2023
Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ Antibiotic allergy Lancet. 2019;393(10167):183–198
Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society Clin Infect Dis. 2016;63(5):e61–e111
Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery Am J Health Syst Pharm. 2013;70(3):195–283
Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America Clin Infect Dis. 2010;50(2):133–164
van de Beek D, Brouwer M, Hasbun R, Koedel U, Whitney CG, Wijdicks E Community-acquired bacterial meningitis Nat Rev Dis Primers. 2016;2:16074
Zhanel GG, Chung P, Adam H, et al. Ceftolozane/tazobactam: a novel cephalosporin/beta-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli Drugs. 2014;74(1):31–51
Drawz SM, Bonomo RA Three decades of beta-lactamase inhibitors Clin Microbiol Rev. 2010;23(1):160–201
Temkin E, Torre-Cisneros J, Beovic B, et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms Antimicrob Agents Chemother. 2017;61(2):e01964-16
Tholakanahalli VN, Pottage JC, Stamos JK Amoxicillin-clavulanate-induced cholestatic hepatitis West J Med. 1996;165(3):202–203
Harris PNA, Tambyah PA, Lye DC, et al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial JAMA. 2018;320(10):984–994
Blumenthal KG, Shenoy ES, Wolfson AR, et al. Addressing inpatient beta-lactam allergies: a multihospital implementation J Allergy Clin Immunol Pract. 2017;5(3):616–625